Professional
Added to YB: 2024-03-13
Pitch date: 2024-03-07
SNY [bullish]
Sanofi
+3.21%
current return
Author Info
No bio for this author
Company Info
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines.
Market Cap
EUR 106.6B
Pitch Price
EUR 80.73
Price Target
61.00 (-27%)
Dividend
4.48%
EV/EBITDA
9.39
P/E
16.78
EV/Sales
2.61
Sector
Pharmaceuticals
Category
growth
Led by Dupixent, Sanofi's Solid Immunology Position Helps Support Steady Long-Term Growth
SNY: Dupixent drives growth, peak sales >€18B. Solid pipeline offsets patents loss; forecast 4% 5yr rev growth. Vaccines, consumer health & emerging markets back steady growth. Conover, CFA: $61 FVE. Mid patent losses & R&D spend pressure margin short-term, poised for post-2030s. Medium risk due to competition/regulatory hurdles. Standard CA Rating, strong BS & investments in rare diseases/immunology. CEO Hudson's leadership to drive efficiency & launches.
Read full article (6 min)